Literature DB >> 18719443

Novel ryanodine receptor mutation that may cause malignant hyperthermia.

Alexius Kaufmann1, Birgit Kraft, Andrea Michalek-Sauberer, Lukas G Weigl.   

Abstract

BACKGROUND: Malignant hyperthermia (MH) is a hypermetabolic condition caused by a genetic disposition leading to increased Ca release from the sarcoplasmic reticulum after exposure to triggering agents. In the authors' ongoing evaluation of patients undergoing MH testing in Austria, they detected a family with a new variant of the ryanodine receptor 1. Guidelines suggest that genetic tests are possible only for individuals from families in which the mutations are known. The aim of this study was to provide functional data that establish a potential link between this new variant and susceptibility to MH, and thus enable application in genetic tests.
METHODS: Messenger RNA was isolated from skeletal muscle cells grown in culture and used for synthesis of complementary DNA, which served as a template for 23 polymerase chain reactions. The sequences of all reaction products were analyzed. Functional studies in differentiated muscle cells included the Ca releasing activity of caffeine and 4-chloro-m-cresol. The authors measured the intracellular Ca concentration and, in combined patch clamp-Ca detection experiments, the voltage dependence of the Ca release.
RESULTS: In a single family, the authors found a transition from a highly conserved thymine to cysteine at position 11953, leading to the exchange of tryptophan to arginine at position 3985. This variant was absent in 100 MH-nonsusceptible individuals. Functionally, cells carrying this variant were more sensitive to caffeine and 4-chloro-m-cresol than wild-type cells and showed a shift in the voltage-dependent Ca release to more negative potentials.
CONCLUSION: These data document a role of the new W3985R variant in MH susceptibility.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18719443     DOI: 10.1097/ALN.0b013e318182a93b

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  5 in total

1.  Kyphoscoliosis associated with congenital neuromuscular disease with uniform type 1 fibers.

Authors:  Shiro Imagama; Noriaki Kawakami; Taichi Tsuji; Tetsuya Ohara; Naoki Ishiguro
Journal:  Eur Spine J       Date:  2011-12-23       Impact factor: 3.134

2.  Ryanodine receptor type 1 gene variants in the malignant hyperthermia-susceptible population of the United States.

Authors:  Barbara W Brandom; Saiid Bina; Cynthia A Wong; Tarina Wallace; Mihaela Visoiu; Paul J Isackson; Georgirene D Vladutiu; Nyamkhishig Sambuughin; Sheila M Muldoon
Journal:  Anesth Analg       Date:  2013-04-04       Impact factor: 5.108

3.  Functional analysis of ryanodine receptor type 1 p.R2508C mutation in exon 47.

Authors:  Takako Migita; Keiko Mukaida; Hiroshi Hamada; Toshimichi Yasuda; Toshiaki Haraki; Ichizo Nishino; Nobuyuki Murakami; Masashi Kawamoto
Journal:  J Anesth       Date:  2009-08-14       Impact factor: 2.078

4.  A recurrent RYR1 mutation associated with early-onset hypotonia and benign disease course.

Authors:  Valérie Biancalana; John Rendu; Annabelle Chaussenot; Helen Mecili; Eric Bieth; Mélanie Fradin; Sandra Mercier; Maud Michaud; Marie-Christine Nougues; Laurent Pasquier; Sabrina Sacconi; Norma B Romero; Pascale Marcorelles; François Jérôme Authier; Antoinette Gelot Bernabe; Emmanuelle Uro-Coste; Claude Cances; Bertrand Isidor; Armelle Magot; Marie-Christine Minot-Myhie; Yann Péréon; Julie Perrier-Boeswillwald; Gilles Bretaudeau; Nicolas Dondaine; Alison Bouzenard; Mégane Pizzimenti; Bruno Eymard; Ana Ferreiro; Jocelyn Laporte; Julien Fauré; Johann Böhm
Journal:  Acta Neuropathol Commun       Date:  2021-09-17       Impact factor: 7.801

5.  Receptor activated Ca(2+) release is inhibited by boric acid in prostate cancer cells.

Authors:  Kimberly Henderson; Salvatore L Stella; Sarah Kobylewski; Curtis D Eckhert
Journal:  PLoS One       Date:  2009-06-23       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.